AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02152410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
Study NCT03880851 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Plan adaptation of Radiation Treatment in case of anatomical changes
Description: Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
Study NCT00573027 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: noninvasive tests
Description: clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
Study NCT02299531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying meal energy density and portion size
Study NCT04623333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT03672695 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: S 64315 (also referred as MIK665) and venetoclax
Description: The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy.
Study NCT02180516 — intervention group
Intervention type: DRUG
Intervention: Meloxicam
Study NCT02180516 — intervention group
Intervention type: DRUG
Intervention: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
Study NCT02696369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine HCl with epinephrine 1:200,000
Study NCT02696369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine HCl with epinephrine 1:80,000
Study NCT00660348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: This is morphine given in the traditional methods.
Study NCT00660348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic intrathecal pump
Description: This pump will be inserted into the research subject and then the pump will deliver morphine.
Study NCT03904706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits only
Description: Formalized audit teams with monthly meetings at each facility.
Study NCT03904706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits with community feedback
Description: This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
Study NCT03811795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ECG monitoring with a Kardia Mobile monitor
Description: The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
Study NCT02311491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic coated orthodontic archwire
Description: Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
Study NCT02581774 — intervention group
Intervention type: OTHER
Intervention: normal delivery tracking
Description: normal delivery tracking
Study NCT03131856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention programme
Description: The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
Study NCT03726177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 162 mg
Description: Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT03726177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 81 mg
Description: Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT03726177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT04656067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin ,Tranexamic acid and Ethamsylate
Description: Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
Study NCT02444091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
Study NCT02869490 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Solution for infusion, 500 mg (250 ml)
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Capsules, 250 mg
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: Solution for infusion, 500 mg (100 ml)
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavanic
Description: Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (250 ml)
Description: 0.9% NaCl (250 ml), solution for infusion
Study NCT03551210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (100 ml)
Description: 0.9% NaCl (100 ml), solution for infusion
Study NCT00366990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Sodium Diet
Description: Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
Study NCT00366990 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular Sodium Intake
Description: Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
Study NCT01239368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
Study NCT01239368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)
Description: Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
Study NCT01239368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Th1/Tc1 Rapa Cell Therapy
Description: Th1/Tc1Rapa: 5 x 10e(6) cells/kg
Study NCT01182493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump (Medtronic Minimed Paradigm® VEO)
Description: The pump delivers insulin as specified by the patient
Study NCT03012100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT03012100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Given PO
Study NCT03012100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03012100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03012100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha Peptide Vaccine
Description: Given ID
Study NCT03012100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID
Study NCT03012100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID
Study NCT03012100 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sargramostim
Description: Given ID
Study NCT02519920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.01ml/kg
Description: fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
Study NCT02519920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.02ml/kg
Description: fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
Study NCT02519920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium 0.05ml/kg
Description: fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
Study NCT02519920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorescein sodium 0.1ml/kg
Description: fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
Study NCT03926351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
Study NCT03443804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test(DW1401)
Description: DW1401+Placebo of Stillen tab.
Study NCT03443804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference(Stillen tab.)
Description: Stillen tab.+Placebo of DW1401
Study NCT02091765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy.
Study NCT02615340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Study NCT02615340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Study NCT00994643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00994643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given SC
Study NCT03170960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
Study NCT03170960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study NCT00719511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 1 integrated in a Patch system
Description: Epicutaneous application of a patch
Study NCT00719511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 2 integrated in a Patch system
Description: Epicutaneous application of a patch
Study NCT00719511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen dose 3 integrated in a Patch system
Description: Epicutaneous application of a patch
Study NCT00719511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified allergen integrated in a Patch system
Description: Epicutaneous application of a patch
Study NCT04102761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradiscal PRP & BMC Injections
Description: The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
Study NCT01393600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 12.5 mg powder in bottle once daily for 14 days
Study NCT01393600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg powder in bottle once daily for 14 days
Study NCT01393600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution containing no active substance
Study NCT04996186 — intervention group
Intervention type: OTHER
Intervention: Clinical interviews
Description: Semi-qualitative interviews and questionnaire STAR-Q
Study NCT02391259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 557
Description: AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
Study NCT02391259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study NCT03048396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Study NCT05601310 — intervention group
Intervention type: DEVICE
Intervention: liquid chromatography-mass spectrometry (LC/MS) analysis
Description: To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
Study NCT02945527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: As described above
Study NCT04102761 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intradiscal PRP & BMC Injections
Description: The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
Study NCT02260804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Description: 375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
Study NCT02260804 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
Study NCT01728870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unique Diet+Partial Enteral Nutrition
Description: Modulen - liquid dietary formula
Study NCT01728870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive Enteral Nutrition (Modulen)
Study NCT01509651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
Study NCT03051906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
Study NCT03051906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
Study NCT03051906 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
Study NCT03222869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measure Airway Resistance Across Stenosis
Description: Measure pressure and air flow Across Stenosis
Study NCT04606225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral) Cozaar Oral Tablet
Study NCT04606225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study NCT01621763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study NCT02945527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: As described above
Study NCT01621763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 300 mg
Study NCT02701374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-700
Study NCT03926351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Soft gelatine capsule containing 1000 mg olive oil, refined.
Study NCT02588963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education session
Description: It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
Study NCT02701374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00944762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecosystem Focused Therapy (EFT)
Description: 12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
Study NCT00944762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education in stroke and depression
Description: Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.